ЧÀÍÈÈÏß
×ðÖØ¿Æѧ ¾´Î·ÖÆ¶È ×·ÇóЧÂÊ ¹Ø°®ÉúÃü
ѧÊõ¶¯Ì¬
Ò¼ºÅÓéÀÖ¹¹½¨ÏµÁÐBa/F3-RET¹¤³Ìϸ°ûÖêÖúÁ¦RETÒÖÖƼÁÑз¢
Ðû²¼Ê±¼ä£º
2020-05-21
Ò¼ºÅÓéÀÖ Ba/F3-RET ϸ°ûÖê
Õë¶ÔRETÒÖÖƼÁÒ©Î￪·¢ÐèÇó£¬ £¬£¬£¬£¬£¬£¬£¬Ò¼ºÅÓéÀÖ¹¹½¨ÏµÁÐBa/F3-RET¹¤³Ìϸ°ûÖ꣬ £¬£¬£¬£¬£¬£¬£¬°üÀ¨×îз¢Ã÷µÄRET-G810R/S/CµÈÄÍÒ©Í»±ä£¬ £¬£¬£¬£¬£¬£¬£¬ÓÃÓÚÕë¶ÔRET°ÐµãµÄ»¯ºÏÎïɸѡÆÀ¼Û¼°¶¯ÎïҩЧÆÀ¼Û£¬ £¬£¬£¬£¬£¬£¬£¬½Ó´ý´¹Ñ¯¡£¡£¡£¡£¡£¡£¡£
ϸ°ûÖêÁбíÈçÏ£º
01 RETÏà¹ØÐźÅͨ·
RET(rearranged during transfection)ÊÇÒ»¸öÔ°©»ùÒò£¬ £¬£¬£¬£¬£¬£¬£¬Î»ÓÚ10ºÅȾɫÌ峤±Û£¬ £¬£¬£¬£¬£¬£¬£¬±àÂëÒ»ÖÖÊÜÌåÀÒ°±Ëἤø(RTK)¡£¡£¡£¡£¡£¡£¡£Í¨³££¬ £¬£¬£¬£¬£¬£¬£¬½ºÖÊϸ°ûÔ´ÐÔÉñı»®ÑøÒò×Ó(Glial cell-line derived neurotrophic factor, GDNF)Ê×ÏÈÓëGFR¦Á1Á¬ÏµÐγÉGDNF-GFR¦Á1¸´ºÏÎ £¬£¬£¬£¬£¬£¬£¬¸Ã¸´ºÏÎïÔÙÓëRETÁ¬ÏµÐγÉÈý¾ÛÌ帴ºÏÎ £¬£¬£¬£¬£¬£¬£¬µ¼ÖÂRETµÄ¶þ¾Û»¯£¬ £¬£¬£¬£¬£¬£¬£¬½øÒ»²½ÒýÆðÀÒ°±Ëá²Ð»ù×ÔÁ×Ëữ£¬ £¬£¬£¬£¬£¬£¬£¬´Ó¶ø¼¤»îÏÂÓÎÐźÅͨ·¡£¡£¡£¡£¡£¡£¡£RETÏÂÓÎÏà¹ØÐźÅͨ·Ö÷Òª°üÀ¨RAS-MAPKºÍPI3K¨CAKTµÈ¡£¡£¡£¡£¡£¡£¡£
02 RET°ÐµãÓëÏà¹Ø°©Ö¢
RET»ùÒòÒì³£»£»£»£»£»£»î»¯Ö÷Òª°üÀ¨»ùÒòÈںϡ¢µãÍ»±ä¡¢¹ý±í´ïÈýÖÖ»úÖÆ£¬ £¬£¬£¬£¬£¬£¬£¬¿Éµ¼Ö¶àÖÖ°©Ö¢¡£¡£¡£¡£¡£¡£¡£RET»ùÒòµãÍ»±äÔÚ¼××´ÏÙËèÑù°©(MTC)Öеı¬·¢ÂÊԼΪ60%-90%£¬ £¬£¬£¬£¬£¬£¬£¬ÆäÖÐ×î³£¼ûµÄÍ»±äλµãÊÇM918T¡£¡£¡£¡£¡£¡£¡£RET»ùÒòÈÚºÏÔÚ¼××´ÏÙÈéÍ·×´°©(PTC)Öб¬·¢ÂÊΪ10%-20%;ÔÚ·ÇСϸ°û·ÎÏÙ°©»¼ÕßÖеı¬·¢ÂÊԼΪ1-2%£¬ £¬£¬£¬£¬£¬£¬£¬ÆäÖÐÒÔKIF5B-RET×îΪ¶à¼û¡£¡£¡£¡£¡£¡£¡£
03 RET ÒÖÖƼÁÑз¢Ã÷×´
ÏÖÔÚ¹ØÓÚRET»ùÒò¸Ä±äÀàÖ×ÁöµÄÖÎÁƼƻ®Ö÷ÒªÊÇʹÓöà°Ðµã¼¤Ã¸ÒÖÖƼÁÀàÒ©Î £¬£¬£¬£¬£¬£¬£¬ºÃ±È¿¨²©ÌæÄá¡¢·²µÂËûÄᣬ £¬£¬£¬£¬£¬£¬£¬ÕâЩҩÎï²»µ«ÒÖÖÆRETÂÑ°×£¬ £¬£¬£¬£¬£¬£¬£¬Í¬Ê±»áÒÖÖÆVEGFR¡¢EGFRµÈÆäËûÂѰס£¡£¡£¡£¡£¡£¡£2020Äê5ÔÂ8ÈÕ£¬ £¬£¬£¬£¬£¬£¬£¬FDA¼ÓËÙÅú×¼ÁËÈ«ÇòÊ׸ö¸ßÑ¡ÔñÐÔRET¼¤Ã¸ÒÖÖƼÁLOXO-292 (selpercatinib £¬ £¬£¬£¬£¬£¬£¬£¬ÀñÀ´)£¬ £¬£¬£¬£¬£¬£¬£¬ºÍÆäËû°ÐÏòÒ©Ò»Ñù£¬ £¬£¬£¬£¬£¬£¬£¬LOXO-292Ò²»áÄÍÒ©¡£¡£¡£¡£¡£¡£¡£ÁÙ´²Ç°Ñо¿ÏÔʾ£¬ £¬£¬£¬£¬£¬£¬£¬RETÈÚºÏNSCLC»¼ÕßʹÓÃLOXO-292ÖÎÁÆºó£¬ £¬£¬£¬£¬£¬£¬£¬¿É±¬·¢G810R/S/CÈܼÁÇ°ÑØÍ»±ä£¬ £¬£¬£¬£¬£¬£¬£¬µ¼ÖÂLOXO-292ÄÍÒ©¡£¡£¡£¡£¡£¡£¡£
ÓÉTurning Point Therapeutics¹«Ë¾¿ª·¢µÄС·Ö×ÓÖƼÁTPX-0046µÄÁÙ´²Ç°Ñо¿Ð§¹ûÏÔʾÆä¶ÔRET-G810R/SÍ»±ä½ÏΪÃô¸Ð£¬ £¬£¬£¬£¬£¬£¬£¬ÒÑ¿ªÕ¹Ò»ÆÚÁÙ´²ÊµÑ飬 £¬£¬£¬£¬£¬£¬£¬ÁíÒ»¿î¿ª·¢ËÙÂʽϿìµÄRETÒÖÖƼÁBLU-667 (pralsetinib £¬ £¬£¬£¬£¬£¬£¬£¬Blueprint¹«Ë¾)ÒÑÏòFDAÌá½»ÁËÉÏÊÐÉêÇë¡£¡£¡£¡£¡£¡£¡£
04 ²¿·Öϸ°ûÑéÖ¤Êý¾Ý
1)Ba/F3-KIF5B-RETÑéÖ¤Êý¾Ý
2)Ba/F3-KIF5B-RET-V804MÑéÖ¤Êý¾Ý
3)Ba/F3-KIF5B-RET-V804LÑéÖ¤Êý¾Ý
4)Ba/F3-KIF5B-RET-G810RÑéÖ¤Êý¾Ý
5)Ba/F3-KIF5B-RET-G810SÑéÖ¤Êý¾Ý
6)Ba/F3-KIF5B-RET-G810CÑéÖ¤Êý¾Ý
ͼƬȪԴ¼Î¿½å¼ÎÄÏ×£º
¡¾1¡¿Advances in Targeting RET-Dependent Cancers. Cancer Discov. ,2020,10:498¨C505.
¡¾2¡¿RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J.Thorac. Oncol.;2020, 15:541-549.
Ò¼ºÅÓéÀÖ¹«ÖÚºÅ
Á¢ÒìÒ©ÎïÆÀ¼Û
ÖпÆÒ½ÂöС³ÌÐò
µç»°£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
꿅᣼www.precedo.cn
µØµã£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°
Copyright © 2021 Ò¼ºÅÓéÀÖ °æȨËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ºÏ·Ê